BIWEEKLY INFUSIONAL 5-FLUOROURACIL (5-FU) AND X-RAYS IN ADVANCED GASTROINTESTINAL CANCER (GICA)

被引：0
|
作者：
BYFIELD, JE
BARONE, R
SEAGREN, S
FRANKEL, S
QUINOL, L
MENDELSOHN, J
机构：
[1] UNIV CALIF SAN DIEGO,DIV RADIAT,LA JOLLA,CA 92037
[2] UNIV CALIF SAN DIEGO,DIV SURG,LA JOLLA,CA 92037
[3] UNIV CALIF SAN DIEGO,DIV MED ONCOL,LA JOLLA,CA 92037
[4] VET ADM HOSP,LA JOLLA,CA 92037
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1978年 / 19卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：322 / 322
页数：1
相关论文
共 50 条
  • [31] PHARMACOKINETICS OF INTRAVITREAL 5-FLUOROURACIL (5-FU) IN THE RABBIT
    LOPEZ, MI
    MATE, A
    MATEU, C
    ALONSO, JI
    PAMPLIEGA, A
    DELNOZAL, MJ
    PASTOR, JC
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1992, 33 (04) : 727 - 727
  • [32] RELATIONSHIP OF GASTROINTESTINAL (GI) PERMEABILITY, GRANULOCYTOPENIA, AND INFECTIONS WITH 5-FLUOROURACIL (5-FU) CHEMOTHERAPY
    SIBER, GR
    MAYER, RJ
    LEVIN, MJ
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 102 - 102
  • [33] SALVAGE TREATMENT WITH CISPLATIN (CDDP) AND 5-FLUOROURACIL (5-FU) IN ADVANCED BREAST-CANCER PATIENTS
    PRONZATO, P
    AMOROSO, D
    BERTELLI, G
    LIONETTO, R
    ARDIZZONI, A
    CONTE, PF
    ROSSO, R
    GALLOTTI, P
    BREAST CANCER RESEARCH AND TREATMENT, 1987, 10 (01) : 108 - 108
  • [34] Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: A critical review of comparative studies
    Labianca, R
    Pessi, A
    Facendola, G
    Pirovano, M
    Luporini, G
    EUROPEAN JOURNAL OF CANCER, 1996, 32A : S7 - S12
  • [35] Enhanced RegIV Expression Predicts the Intrinsic 5-Fluorouracil (5-FU) Resistance in Advanced Gastric Cancer
    Ying, Li-Sha
    Yu, Jiang-Liu
    Lu, Xiao-Xiao
    Ling, Zhi-Qiang
    DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (02) : 414 - 422
  • [36] Enhanced RegIV Expression Predicts the Intrinsic 5-Fluorouracil (5-FU) Resistance in Advanced Gastric Cancer
    Li-Sha Ying
    Jiang-Liu Yu
    Xiao-Xiao Lu
    Zhi-Qiang Ling
    Digestive Diseases and Sciences, 2013, 58 : 414 - 422
  • [37] SEQUENTIAL CHEMOTHERAPY OF 5-FLUOROURACIL (5-FU) AND METHOTREXATE (MTX) IN THE REGIMEN OF CYTOXAN (CTX), MTX AND 5-FU IN THE TREATMENT OF ADVANCED BREAST-CANCER
    CHANG, JC
    HILL, G
    EDISS, G
    REILING, W
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 404 - 404
  • [38] QUANTITATIVE ASPECTS OF COMBINED INFUSIONAL 5-FU AND RADIATION IN ADVANCED CANCER
    BYFIELD, JE
    BRITISH JOURNAL OF CANCER, 1981, 44 (02) : 288 - 289
  • [39] The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients
    Scartozzi, M
    Sobrero, A
    Gasparini, G
    Berardi, R
    Catalano, V
    Graziano, F
    Barni, S
    Zaniboni, A
    Beretta, GD
    Labianca, R
    Cascinu, S
    ONCOLOGY, 2005, 68 (2-3) : 212 - 216
  • [40] RANDOMIZED TRIAL OF MELPHALAN PLUS 5-FLUOROURACIL (5-FU) VERSUS METHYL-CCNU PLUS 5-FU IN PATIENTS WITH ADVANCED COLORECTAL CANCER
    BERMAN, R
    GILES, GR
    MALHOTRA, A
    BIRD, GG
    GAJJAR, PD
    BUNCH, GA
    HALL, R
    CANCER TREATMENT REPORTS, 1978, 62 (03): : 457 - 459
12345